Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing first-in-class phosphatidylserine (PS)-targeting monoclonal antibodies for the treatment of cancer and viral infections, announced the launch of an investigator-sponsored trial (IST) program for bavituximab and Cotara. Bavituximab is a novel approach to treating cancer and viral infections and has demonstrated promising interim results in ongoing Phase 2 clinical trials in non-small cell lung cancer (NSCLC) and advanced breast cancer. Cotara is a brain cancer therapy currently in a Phase II clinical trial for recurrent glioblastoma multiforme (GBM), and has generated promising survival data in earlier studies.
“Even before formally announcing our IST program, we have been receiving an increasing number of requests from investigators interested in conducting clinical studies with either bavituximab or Cotara, and we are eager to evaluate proposals and begin working with investigators to start new clinical studies,” commented Marvin R. Garovoy, M.D., head of clinical science at Peregrine. “The launch of our new IST program comes as we prepare to present additional data from multiple clinical studies at upcoming conferences and provide updates to the oncology community. We believe our IST program can provide valuable information on mechanisms of action, use in additional oncology indications, and application in different therapeutic combinations, and we welcome the opportunity to offer this program to oncologists who share our excitement over the clinical potential of our novel agents.”
This program offers oncologists the opportunity to conduct clinical trials for Cotara in brain cancer and bavituximab in the following indications:
· Breast cancer
· Fibrosarcoma
· Brain cancer
· Hodgkin’s lymphoma
· Non-small cell lung cancer
· Pancreatic cancer
· Prostate cancer
· Colorectal cancer
· Melanoma
· Renal cancer
· Urinary bladder cancer
· Hepatocellular carcinoma
· Ovarian cancer
Date: April 12, 2010
Source: Peregrine Pharmaceuticals, Inc.
